Related Experiment Videos
Therapy for nosocomial pneumonia
1University of Tennessee at Memphis 38105, USA.
Abstract:
Because of a lack of clinical trials, the American Thoracic Society published a consensus statement on nosocomial pneumonia that included recommendations for antibiotic therapy. Almost concurrently, a multicenter study of the need to modify antibiotic therapy in ventilator-associated pneumonia (VAP) and a report specifically studying Pseudomonas VAP independently demonstrated both the appropriateness and some of the inadequacies of the therapies recommended by the American Thoracic Society. Anaerobic involvement as a copathogen was documented in early-onset VAP but probably impacts antibiotic choices little because of the presence of aerobic pathogens. Potential improvements in aminoglycoside treatment were suggested by meta-analysis of once-daily dosing and aerosolization. The most provocative study used decision-analysis techniques to suggest that antibiotic therapy based on clinical diagnosis of VAP would result in greater mortality than withholding antibiotics. Diagnosis of VAP by bronchoscopic and nonbronchoscopic quantitative cultures resulted in improved outcome with antibiotic treatment, possibly the result of documentation of inappropriate empiric antibodies in approximately 40% of cases of late-onset VAP.
Insights
Antibiotic therapy for ventilator-associated pneumonia (VAP) needs refinement. Quantitative cultures improve outcomes, suggesting current empiric antibiotic choices are often inadequate for VAP treatment.
Area of Science:
- Critical Care Medicine
- Infectious Diseases
- Pulmonology
Background:
- The American Thoracic Society issued guidelines for nosocomial pneumonia antibiotic therapy due to limited clinical trials.
- Multicenter studies and specific pathogen reports revealed both the utility and limitations of these ATS-recommended therapies for ventilator-associated pneumonia (VAP).
Purpose of the Study:
- To evaluate the current antibiotic therapy recommendations for ventilator-associated pneumonia (VAP).
- To assess the impact of diagnostic methods and specific pathogens on VAP treatment efficacy.
Main Methods:
- Review of a consensus statement on nosocomial pneumonia.
- Analysis of multicenter studies on VAP antibiotic therapy modification.
- Examination of studies on Pseudomonas VAP and anaerobic copathogens.
- Meta-analysis of aminoglycoside dosing and aerosolization.
- Decision-analysis modeling for VAP antibiotic treatment strategies.
- Comparison of bronchoscopic and nonbronchoscopic quantitative cultures for VAP diagnosis.
Main Results:
- ATS-recommended therapies for VAP showed both appropriateness and inadequacies.
- Anaerobic pathogens were identified in early-onset VAP but had minimal impact on antibiotic choices.
- Once-daily aminoglycoside dosing and aerosolization showed potential treatment improvements.
- Decision analysis suggested withholding antibiotics based on clinical diagnosis could increase mortality.
- Quantitative cultures for VAP diagnosis improved outcomes, identifying inappropriate empiric antibiotics in ~40% of late-onset cases.
Conclusions:
- Current empiric antibiotic therapy for VAP, particularly late-onset, is frequently inappropriate.
- Quantitative culture-guided antibiotic selection improves patient outcomes in VAP.
- Refined diagnostic and therapeutic strategies are crucial for optimizing VAP management.